Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated armodafinil 150 mg/day as adjunctive therapy for adults with major depression associated with bipolar I disorder; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• Armodafinil (armodafinil)

Snippet

Sponsor: Cephalon | Conditions: Depression | Phase 3 | Status: COMPLETED | Results posted: 2015-01-26